| Clinical Analysis on Improvement of Bone Quality after Vitamin K2 (Menatetrenone)
Administration in Osteoporosis Patients with/without Osteoporotic Compression Fracture |
|
Jong Il Choe , Jung Yul Park , Sang Dae Kim , Se Hoon Kim, Dong Jun Lim , Jung-Keun Suh |
|
Department of Neurosurgery, College of Medicine Korea Universit, Korea |
| 골다공증 환자와 골다공증성 척추체 압박골절 환자에서 Vitamin
K2 (Menatetrenone) 투여 후 골질 향상에 대한 임상 분석 |
|
최종일ㆍ박정율ㆍ김상대ㆍ김세훈ㆍ임동준ㆍ서중근 |
|
고려대학교 의과대학 신경외과학교실 |
|
|
| Abstract |
Objective
The radiographic and bone mineral density (BMD) results have been generally used to evaluate the presence and progression
of osteoporosis. However, they may not reflect the actual qualities of bone and thus other studies may sometimes be necessary
to assess the qualities of bone (e.g., bone forming and bone resorption status). We studied serum C-peptide protein (CTx) and osteocalcin
in osteoporosis patients with or without osteoporotic compression fracture after administration of Vitamin K2 (Menatetrenone)
to investigate the improvement of bone quality.
Methods
We analyzed 61 patients with osteoporosis with or without osteoporotic vertebral compression fracture. We divided these
patients into two groups; Group I included chronic osteoporosis patients with back pain who were prescribed with only Vitamin K2
(n=33), and Group II included patients with acute osteoporotic compression fracture initially treated percutaneous kyphoplasty, and
then medicated with Vitamin K2 (n=28). Serum level of C-peptide protein (CTx) and osteocalcin were measured before the treatment
and, 12 weeks of the follow-up period. Also, additional occurrences of osteoporotic compression fractures were monitored during the
follow-up period.
Results
C-peptide protein (CTx) was increased in 19 (57%) patients and decreased in 14 (43%) patients in Group I patients while
it was increased in 5 (17%) patients and decreased in 23 (83%) in Group II patients. Oseteocalcin was increased in 17 (51%) patients
and decreased in 16 (49%) in Group I patients while it was increased in 19 (67%) patients and decreased in 9 (33%) in Group II
patients. Three patients were detected to have new osteoporotoc compression fractures during follow up period; 2 from Group I (6%
of the patients) and 1 (3%) from Group 2..
Conclusion
It has shown that vitamin K2 (menatetrenone) substantially provides beneficial effect on bone qualities in patients with
osteoporotic vertebral compression fractures, especially in patients with vertebral augmentation procedure following acute osteoporotic
compression fracture. Further study will be necessary to demonstrate its role in patients with severe osteoporosis without compression
fracture, especially in regards with its protective effect on development of additional compression fracture. |
| Key Words:
Vitamin K2 (Menatetrenone)ㆍOsteoporotic compression fractureㆍOsteoporosisㆍC-peptide protein (CTx)ㆍOseteocalcin |
|
PDF Links
Download Citation
